Recent advancements in HIV treatment and prevention, including the roll-out of pre-exposure prophylaxis (PrEP) and the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen, have highlighted the critical need for ethnic-centered approaches in healthcare.Therefore, understanding
GI Innovation is accelerating the development of a subcutaneous (SC) formulation of its immuno-oncology candidate GI-102.The company said Tuesday that it has applied for approval to change the IND (investigational new drug) application for the GI-102 phase 1/2a clinical trial to the Ministry of Food
Saruparib, a next-generation PARP inhibitor in development by AstraZeneca, has garnered attention from cancer experts worldwide after showing clinical benefit in patients with homologous recombination repair-deficient (HRD) breast cancer.However, it is questionable whether Korean patients who face s
Curocell, a local chimeric antigen receptor-T (CAR-T) developer, said it will start developing a next-generation Anti-CD19 CAR-T therapy for treatment-resistant systemic lupus erythematosus (SLE) as part of the2024 Multi-Ministerial Regenerative Medicine Technology Development Program.This initiativ
Hugel, a total medical aesthetics company, said Tuesday that its polydioxanone (PDO) suture brand Licellvi (domestic product name: Blue Rose Forte) has received a product license from the Brazilian National Agency for Food and Drug Surveillance (ANVISA).Licellvi is a PDO suture brand of JWorld, a su
An increasing number of health supplements are differentiating themselves from traditional forms, such as capsules and pills, to various formulations, attempting to attract consumers with formulations that focus on portability and convenience of consumption.CJ ENM's digital marketing affiliate, Mezz
Daewoong Pharmaceutical said that it applied for product approval for Envlo, the first homegrown sodium-glucose cotransporter 2 (SGLT2) diabetes drug in Korea and the nation's 36th newly developed drug, to Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS).COFEPRIS is
Celltrion said it has completed a registration contract for its subcutaneous (SC) Remicade biosimilar, Zymfentra (infliximab), with one of the top three pharmaceutical benefit managers (PBMs) in the United States."We are pleased to announce through our website that we have successfully closed a deal
EuBiologics, a Korean vaccine maker targeting the global public health market, said it opened a new office at the Cambridge Innovation Center (CIC) in Boston, one of the largest biotech clusters in the world.EuBiologics' new office opening comes after their selection by KHIDI (Korea Health Industry
In a move signaling a potential resolution to ongoing family disputes, Hanmi Science, the holding company of Hanmi Pharm, announced the appointment of Lim Jong-hoon as co-CEO alongside the current chairperson, Song Young-sook.The decision came during a board meeting held at Hanmi headquarters in Son
BR Pharm, a regenerative medicine company, said it would present "Minimizing Procedural Pain and Maintaining Effectiveness" related to HP VITARAN, a skin booster using PN (Polynucleotide Sodium), at APS (AESTHETIC PLASTIC SURGERY) 2024, which will be held at the Grand InterContinental Seoul Parnas S
Eylea Injection 8 mg (aflibercept), which sharply increased the dose from the existing Eylea Injection 2 mg,, has won approval in Korea, drawing attention to whether it will be able to defend its leading position in the retinal disease market from Roche's Vabysmo (faricimab) and Eylea biosimilars.On
The Fair Trade Commission (FTC) is reportedly looking into Novo Nordisk Korea over allegations of monopolistic practices related to the cessation of its needle supply, NovoFine Plus pen needle.On Thursday, Joongang Ilbo, a Korean daily newspaper, first reported that the FTC's Seoul office dispatched
GC Cell, a contract development and manufacturing organization (CDMO) for cell and gene therapies, said Thursday that it has ushered in Kang Jin-hee, a clinical development and global regulatory expert, as its chief development officer to strengthen its R&D capabilities.According to GC Cell, the new
Boryung (formerly Boryung Pharmaceutical), a strong player in the domestic anticancer drug market, draws the industry’s attention by tying up with Bixink Therapeutics, which holds the domestic rights to Nerlynx Tablets (neratinib maleate), a new drug for HER2-positive breast cancer.Bixink Therapeuti
The Ministry of Health and Welfare, in collaboration with the Korea Health Industry Development Institute and Novo Nordisk, hosted the "Novo Nordisk Partnering Day- Korea 2024" on Thursday.The two-day event, part of a broader open innovation initiative, aims to foster collaboration between startups
Astellas Pharma Korea said it hosted the Satellite Symposium during the 2024 International Congress of the Korean Society of Hematology (ICKSH 2024) held at the Grand Walker Hill Seoul from March 28 to 30 to share the latest advances in the treatment of acute myeloid leukemia (AML).Professor Naoko H
Vivozon Group, comprising Vivozon and Vivozon Pharmaceutical, has joined forces with Boryung to commercialize Vivozon's domestically developed non-narcotic painkiller, opiranserin (VVZ-149), in Korea.The partnership was formalized through a memorandum of understanding (MOU) signed on Wednesday, whic
Kukje Pharma said Tuesday that it has signed a strategic marketing partnership contract with Celltrion for the domestic sales of Celltrion's CT-P42 (aflibercept), an Eylea biosimilar, for treating ophthalmic retinal diseases.Under the agreement, Celltrion will exclusively provide Kukje Pharma with d
AbbVie Korea said the Korean health insurance coverage for Rinvoq (upadacitinib), a once-daily, oral, selective and reversible JAK1 inhibitor, has been expanded to treat moderately to severely active ulcerative colitis and Crohn's disease in adults, effective from April 1. Rinvoq is covered by healt
